Interlink provides Januvia pre-launch med ed

Interlink Healthcare Communications will provide pre-launch medical education for Merck's Januvia (sitagliptin), a DPP-4 inhibitor for treating type II diabetes. Januvia is expected to be decided on by the FDA in October.
You must be a registered member of MMM to post a comment.